Quarterly ResultMay 12, 2026, 05:11 PM
COSCIENS Biopharma Q1 Net Income $10.8M; Plans to Suspend SEC Reporting
AI Summary
COSCIENS Biopharma reported a consolidated net income of $10.8 million for Q1 2026, a significant increase from a $3.7 million net loss in Q1 2025, primarily due to a $10.9 million income from discontinued operations following the deconsolidation of its German subsidiaries. The company also saw a reduced net loss from continuing operations of $0.2 million and increased total revenue to $1.9 million. Additionally, COSCIENS plans to suspend its SEC reporting obligations, with shareholders to vote on a share reorganization on June 17, 2026, and has decided not to advance its AvenActive program.
Key Highlights
- Consolidated net income of $10.8 million ($3.42 EPS) in Q1 2026, up from a $3.7 million net loss in Q1 2025.
- Income from discontinued operations of $10.9 million recognized upon deconsolidation of German subsidiaries.
- Consolidated net loss from continuing operations decreased to $0.2 million ($0.06 loss per share) from $2.7 million in Q1 2025.
- Total revenue increased to $1.9 million in Q1 2026 from $1.4 million in Q1 2025.
- Total operating expenses decreased to $1.5 million from $3.0 million in Q1 2025.
- Cash and cash equivalents stood at $5.0 million at March 31, 2026.
- Company plans to suspend SEC reporting obligations, with a shareholder vote on June 17, 2026.
- Decided not to advance the AvenActive program after Phase 2a study results were not statistically significant.